These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3022677)

  • 21. Quantitative relationships between an influenza virus and neutralizing antibody.
    Taylor HP; Armstrong SJ; Dimmock NJ
    Virology; 1987 Aug; 159(2):288-98. PubMed ID: 3617501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide priming of a poliovirus neutralizing antibody response.
    Wimmer E; Emini EA; Jameson BA
    Rev Infect Dis; 1984; 6 Suppl 2():S505-9. PubMed ID: 6330847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
    Taniguchi K; Urasawa S; Urasawa T
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization and sensitization of cytomegalovirus by IgG antibody, anti-IgG antibody, and complement.
    Rundell BB; Betts RF
    J Med Virol; 1982; 10(2):109-18. PubMed ID: 6292359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions.
    Blondel B; Akacem O; Crainic R; Couillin P; Horodniceanu F
    Virology; 1983 Apr; 126(2):707-10. PubMed ID: 6190311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folding and processing of the capsid protein precursor P1 is kinetically retarded in neutralization site 3B mutants of poliovirus.
    Reynolds C; Birnby D; Chow M
    J Virol; 1992 Mar; 66(3):1641-8. PubMed ID: 1310770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hit-and-run neutralization of poliovirus.
    Brioen P; Rombaut B; Boeyé A
    J Gen Virol; 1985 Nov; 66 ( Pt 11)():2495-9. PubMed ID: 2997379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monospecific antisera against capsid polypeptides of poliovirus type 1 distinguish antigenic structures of poliovirus proteins.
    Wiegers KJ; Dernick R
    J Gen Virol; 1983 Apr; 64 (Pt 4)():777-85. PubMed ID: 6300300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity?
    Yoden S; Kida H; Yanagawa R
    Arch Virol; 1985; 85(3-4):209-16. PubMed ID: 2411245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines.
    Zhaori G; Sun M; Faden HS; Ogra PL
    J Infect Dis; 1989 Jun; 159(6):1018-24. PubMed ID: 2470831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.
    Li Q; Yafal AG; Lee YM; Hogle J; Chow M
    J Virol; 1994 Jun; 68(6):3965-70. PubMed ID: 7514682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.
    Ferguson M; Schild GC; Minor PD; Yates PJ; Spitz M
    J Gen Virol; 1981 Jun; 54(Pt 2):437-42. PubMed ID: 6270261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient neutralization of foot-and-mouth disease virus by monovalent antibody binding.
    Verdaguer N; Fita I; Domingo E; Mateu MG
    J Virol; 1997 Dec; 71(12):9813-6. PubMed ID: 9371652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of cytomegalovirus immune complexes with host cells.
    Rundell BB; Betts RF
    Infect Immun; 1981 Sep; 33(3):658-65. PubMed ID: 6269997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-reactions of immunoglobulin M and G antibodies with enterovirus-specific viral structural proteins.
    Reigel F; Burkhardt F; Schilt U
    J Hyg (Lond); 1985 Oct; 95(2):469-81. PubMed ID: 2999228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.